Shire, and Santaris Extend Alliance to Develop LNA-drugs - - BioPharm International

ADVERTISEMENT

Shire, and Santaris Extend Alliance to Develop LNA-drugs



Santaris Pharma, a biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has extended its existing partnership with Shire for treatments for rare genetic diseases. 

Under the terms of the extended agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development.  Santaris will receive an upfront payment and, consistent with the initial agreement, is eligible for research support, pre-clinical, clinical, and sales milestones, as well as royalties on each product emerging from the collaboration.

Source: Santaris Pharma

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Merck KGaA Breaks Ground on Facility in China
September 5, 2014
DPT Laboratories Acquires Media Pharmaceuticals' Lakewood Facilities
September 5, 2014
Author Guidelines

Click here